|
View: |
Part 1: Document Description
|
|
Citation |
|
|---|---|
|
Title: |
Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, SingleCenter Clinical Trial |
|
Identification Number: |
doi:10.7910/DVN/MIBSTZ |
|
Distributor: |
Harvard Dataverse |
|
Date of Distribution: |
2023-12-21 |
|
Version: |
1 |
|
Bibliographic Citation: |
Ranjith Ramasamy, 2023, "Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, SingleCenter Clinical Trial", https://doi.org/10.7910/DVN/MIBSTZ, Harvard Dataverse, V1 |
|
Citation |
|
|
Title: |
Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, SingleCenter Clinical Trial |
|
Identification Number: |
doi:10.7910/DVN/MIBSTZ |
|
Authoring Entity: |
Ranjith Ramasamy (Desai Sethi Urology Institute, University of Miami Miller School of Medicine) |
|
Distributor: |
Harvard Dataverse |
|
Access Authority: |
Ranjith Ramasamy |
|
Depositor: |
Park, Hyun Jun |
|
Date of Deposit: |
2023-12-21 |
|
Holdings Information: |
https://doi.org/10.7910/DVN/MIBSTZ |
|
Study Scope |
|
|
Keywords: |
Medicine, Health and Life Sciences |
|
Abstract: |
Purpose: To evaluate patient satisfaction and symptom control in hypogonadal men transitioning from other testosterone therapies to oral testosterone undecanoate (TU). Materials and Methods: In this open-label clinical trial, men aged 18 to 75 years with hypogonadism were switched to oral TU after a sufficient washout of previous testosterone therapies. Treatment satisfaction and symptom control were primarily measured using the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) and quantitative androgen deficiency in aging males (qADAM) questionnaires, respectively. Secondary outcomes included changes in serum testosterone (T), estradiol (E2), hematocrit (HCT), and prostate-specific antigen (PSA) levels. Results: Forty-one men participated, with significant improvements in all TSQM-9 scores observed over 6 months. Symptom control as measured by qADAM remained consistent. There was a significant increase in serum T and E2 levels, but HCT and PSA levels remained stable. Conclusions: Switching to oral TU from other testosterone therapies is associated with increased patient satisfaction and stable hypogonadal symptom control. |
|
Methodology and Processing |
|
|
Sources Statement |
|
|
Data Access |
|
|
Other Study Description Materials |
|
|
Related Publications |
|
|
Citation |
|
|
Title: |
pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online M D, 2023 https://doi.org/10.5534/wjmh.230164 |
|
Bibliographic Citation: |
pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online M D, 2023 https://doi.org/10.5534/wjmh.230164 |
|
Label: |
Jatenzo Data Cleaned 052523.xlsx |
|
Notes: |
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet |